Results 11 to 20 of about 29,392 (188)

Apixaban as a Rare Cause of Leukocytoclastic Vasculitis

Case Reports in Rheumatology, 2020
Apixaban is a rare cause of leukocytoclastic vasculitis (LCV). To our knowledge, there is only one other reported case due to apixaban in the literature. We present a case of apixaban-induced leukocytoclastic vasculitis in a 95-year-old male. He had been
Jenna Spears, David Alexandre Chetrit, Sina Manthey, Christopher Lee, Yousif Al-Saiegh   +4 more
doaj   +2 more sources

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

Clinical Pharmacology: Advances and Applications, 2013
Vijay V Upreti,1 Yan Song,1 Jessie Wang,2 Wonkyung Byon,3 Rebecca A Boyd,3 Janice M Pursley,4 Frank LaCreta,1 Charles E Frost1 1Clinical Pharmacology and Pharmacometrics, Discovery Medicine and Clinical Pharmacology, 2Exploratory Development Global ...
Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, LaCreta F, Frost CE   +7 more
doaj   +1 more source

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

TH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz   +7 more
doaj   +2 more sources

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects

Clinical Pharmacology: Advances and Applications, 2017
Charles Frost,1 Yan Song,1 Zhigang Yu,2 Jessie Wang,3 Lois S Lee,4 Alan Schuster,5 Allyson Pollack,1 Frank LaCreta1 1Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA; 2Medical Sciences, Amgen Asia R&D Center ...
Frost C, Song Y, Yu Z, Wang J, Lee LS, Schuster A, Pollack A, LaCreta F   +7 more
doaj   +1 more source

Thrombin generation in HeartMate 3 patients on apixaban and vitamin K antagonists: Variability limits clinical applicability [PDF]

JHLT Open
Apixaban is increasingly replacing vitamin K antagonists (VKAs) during HeartMate 3 (HM3) left ventricular assist device support, but its pharmacodynamics in this setting remain poorly understood.
Charlotte J. Van Edom, MD, Walter Droogné, MD, Steven Jacobs, MD, PhD, Marc Jacquemin, MD PhD, Christine Van Laer, PhD, Joeri Van Puyvelde, MD, PhD, Dirk Vlasselaers, MD, PhD, Katrien Vandersmissen, Thomas Vanassche, MD, PhD, Bart Meyns, MD, PhD   +9 more
doaj   +2 more sources

Efficacy and Safety of Apixaban Thromboprophylaxis According to Baseline Chemotherapy Class in High-Risk Ambulatory Cancer Patients: A Post Hoc Analysis of the AVERT Trial. [PDF]

Cancer Med
ABSTRACT Background Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer patients. The AVERT trial showed apixaban thromboprophylaxis reduced VTE in intermediate‐to‐high‐risk patients initiating chemotherapy. However, the efficacy and safety of apixaban according to baseline chemotherapy class remain incompletely ...
Feng NL, Doering J, Wang TF, Mallick R, Le Gal G, Shaw J, Hill D, Shivakumar S, Tagalakis V, Wells P, Carrier M.   +10 more
europepmc   +2 more sources

Pharmacokinetics and pharmacogenetics of apixaban [PDF]

, 2020
© 2020 Stolichnaya Izdatelskaya Kompaniya. All rights reserved. Apixaban is oral anticoagulant, it is widely used in prevention of stroke in non-valvular atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism. Its main mechanism
Bochanova E.N., Petrova M.M., Nasyrova R.F., Shnayder N.A., Savinova A.V.   +4 more
core   +2 more sources

Quick reference guide to apixaban [PDF]

, 2017
Katherine Victoria Hurst, John Matthew O’Callaghan, Ashok Handa Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK Abstract: Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting ...
Handa A, O'Callaghan JM, Hurst KV
core   +2 more sources

A Dangerous and Unrecognized Interaction of Apixaban [PDF]

, 2021
Direct oral anticoagulants (DOACs) drug-to-drug interactions are underrecognized by clinicians. Apixaban has cytochrome 450 (CYP) mediated metabolism (primarily by CYP3A4).
Govindu, Rukma R, Ammar, Hussam, Rukma R Govindu, Hussam Ammar   +3 more
core   +1 more source

Critical Analysis of Apixaban Dose Adjustment Criteria

Clinical and Applied Thrombosis/Hemostasis, 2021
Apixaban is indicated for the prevention of ischemic stroke in non-valvular atrial fibrillation (NVAF), as well as for the prevention and treatment of venous thromboembolism (VTE).
Anh Vu PharmD, Tao T. Qu PharmD, Rachel Ryu PharmD, BCPS, Shuktika Nandkeolyar MD, Alan Jacobson MD, Lisa T. Hong PharmD, BCPS   +5 more
doaj   +1 more source